AtriCure (ATRC) Competitors $31.50 -0.04 (-0.13%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATRC vs. ITGR, IART, ATEC, OFIX, SRDX, ANGO, ARAY, RMTI, RSLS, and ABTShould you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Integer (ITGR), Integra LifeSciences (IART), Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), and Abbott Laboratories (ABT). These companies are all part of the "health care equipment" industry. AtriCure vs. Integer Integra LifeSciences Alphatec Orthofix Medical Surmodics AngioDynamics Accuray Rockwell Medical ReShape Lifesciences Abbott Laboratories Integer (NYSE:ITGR) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations. Do analysts prefer ITGR or ATRC? Integer presently has a consensus target price of $145.44, indicating a potential upside of 6.38%. AtriCure has a consensus target price of $42.00, indicating a potential upside of 33.33%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Integer.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Integer 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89AtriCure 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ITGR or ATRC? AtriCure received 172 more outperform votes than Integer when rated by MarketBeat users. Likewise, 69.14% of users gave AtriCure an outperform vote while only 63.92% of users gave Integer an outperform vote. CompanyUnderperformOutperformIntegerOutperform Votes38863.92% Underperform Votes21936.08% AtriCureOutperform Votes56069.14% Underperform Votes25030.86% Do institutionals & insiders have more ownership in ITGR or ATRC? 99.3% of Integer shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 2.0% of Integer shares are owned by company insiders. Comparatively, 3.2% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to ITGR or ATRC? In the previous week, Integer and Integer both had 7 articles in the media. AtriCure's average media sentiment score of 0.96 beat Integer's score of 0.83 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ITGR or ATRC more profitable? Integer has a net margin of 6.70% compared to AtriCure's net margin of -8.70%. Integer's return on equity of 11.63% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets Integer6.70% 11.63% 5.86% AtriCure -8.70%-8.12%-6.21% Which has better valuation and earnings, ITGR or ATRC? Integer has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInteger$1.71B2.68$90.65M$3.2442.20AtriCure$447.57M3.43-$30.44M-$0.83-37.95 Which has more volatility & risk, ITGR or ATRC? Integer has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. SummaryInteger and AtriCure tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRC vs. The Competition Export to ExcelMetricAtriCureSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.54B$4.41B$5.20B$9.31BDividend YieldN/A44.87%4.80%4.06%P/E Ratio-37.9525.00128.1117.53Price / Sales3.4346.561,260.62139.54Price / CashN/A44.2041.3637.95Price / Book3.207.254.894.92Net Income-$30.44M$13.83M$119.92M$225.78M7 Day Performance-5.43%-2.91%16.64%-1.56%1 Month Performance-9.27%3.03%16.35%6.68%1 Year Performance-10.69%47.13%35.47%22.48% AtriCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRCAtriCure3.6352 of 5 stars$31.50-0.1%$42.00+33.3%-11.7%$1.54B$447.57M-37.951,200Analyst ForecastPositive NewsITGRInteger2.8267 of 5 stars$139.62+0.7%$145.44+4.2%+40.1%$4.68B$1.71B43.0310,500IARTIntegra LifeSciences4.0854 of 5 stars$24.05+0.1%$23.00-4.4%-46.2%$1.86B$1.56B-267.003,946News CoveragePositive NewsATECAlphatec3.9746 of 5 stars$9.48-1.5%$17.11+80.5%-29.1%$1.34B$572.74M-7.52700Short Interest ↑OFIXOrthofix Medical2.9536 of 5 stars$18.22+1.4%$23.00+26.2%+47.9%$696.19M$746.64M0.001,634Short Interest ↓Positive NewsSRDXSurmodics4.6223 of 5 stars$40.020.0%$50.00+24.9%+5.9%$573.49M$126.08M-49.42376Analyst ForecastNews CoveragePositive NewsANGOAngioDynamics4.4146 of 5 stars$9.32+3.6%$12.00+28.8%+23.8%$378.71M$292.73M-1.51748ARAYAccuray4.657 of 5 stars$1.94+0.8%$9.00+365.1%-28.5%$194.59M$444.20M-11.29987Positive NewsRMTIRockwell Medical4.2725 of 5 stars$2.06+1.0%$6.00+191.3%+27.2%$66.58M$98.92M-41.20300News CoverageGap UpRSLSReShape Lifesciences1.1389 of 5 stars$4.65-1.5%N/A-76.1%$3.30M$8.68M0.0050Positive NewsGap UpABTAbbott Laboratories4.9335 of 5 stars$113.55+0.1%$130.71+15.1%+5.6%$196.95B$41.22B34.46114,000Dividend IncreaseShort Interest ↑ Related Companies and Tools Related Companies ITGR Competitors IART Competitors ATEC Competitors OFIX Competitors SRDX Competitors ANGO Competitors ARAY Competitors RMTI Competitors RSLS Competitors ABT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATRC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
